Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture

Vascular Pharmacology

Volumn 80, Issue , 2016, Pages 50-58

  Roth, Lynn ^a   Rombouts, Miche ^a   Schrijvers, Dorien M ^a   Martinet, Wim ^a   De Meyer, Guido R Y ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Coronary stenosis; Inflammatory cytokines; Matrix metalloproteinases; Myocardial infarction; Pleiotropic effects

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; COLLAGEN TYPE 1; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LIPOPROTEIN; MACROPHAGE ELASTASE; TUMOR NECROSIS FACTOR ALPHA; FBN1 PROTEIN, MOUSE; FIBRILLIN 1; HYPOCHOLESTEROLEMIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR MORBIDITY; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FAST PROTEIN LIQUID CHROMATOGRAPHY; FAT INTAKE; FEMALE; FLOW CYTOMETRY; HEART FUNCTION; HEART INFARCTION; IMMUNOCOMPETENT CELL; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MONOCYTE; MORBIDITY; MOUSE; MOUSE MODEL; NEUTROPHIL; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUDDEN DEATH; T LYMPHOCYTE; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING; WESTERN DIET; ANIMAL; ANIMAL FOOD; BLOOD; DEFICIENCY; DISEASE MODEL; GENETICS; HYPERCHOLESTEROLEMIA; IMMUNOLOGY; KAPLAN MEIER METHOD; KNOCKOUT MOUSE; PLAQUE, ATHEROSCLEROTIC; SURVIVAL ANALYSIS;

ANIMAL FEED; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; ATORVASTATIN CALCIUM; CHOLESTEROL; DISEASE MODELS, ANIMAL; FEMALE; FIBRILLIN-1; HYPERCHOLESTEROLEMIA; KAPLAN-MEIER ESTIMATE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; SURVIVAL ANALYSIS;

EID: 84961872954     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2016.01.007     Document Type: Article

References (42)

1. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
2. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N. Engl. J. Med. 2013, 368:2004-2013.
3. Yla-Herttuala S., Bentzon J.F., Daemen M., Falk E., Garcia-Garcia H.M., Herrmann J., et al. Stabilization of atherosclerotic plaques: an update. Eur. Heart J. 2013, 34:3251-3258.
4. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2012, 33:1635-1701.
5. Calabro P., Yeh E.T.H. The pleiotropic effects of statins. Curr. Opin. Cardiol. 2005, 20:541-546.
6. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
7. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:III39-III43.
8. McFarlane S.I., Muniyappa R., Francisco R., Sowers J.R. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J. Clin. Endocrinol. Metab. 2002, 87:1451-1458.
9. Zadelaar S., Kleemann R., Verschuren L., de Vries-Van der Weij J., van der Hoorn J., Princen H.M., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1706-1721.
10. Van der Donckt C., Van Herck J.L., Schrijvers D.M., Vanhoutte G., Verhoye M., Blockx I., et al. Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. Eur. Heart J. 2015, 36:1049-1058.
11. Van Herck J.L., De Meyer G.R.Y., Martinet W., Van Hove C.E., Foubert K., Theunis M.H., et al. Impaired fibrillin-1 function promotes features of plaque instability in apolipoprotein e-deficient mice. Circulation 2009, 120:2478-2487.
12. Yla-Herttuala S., Bentzon J.F., Daemen M., Falk E., Garcia-Garcia H.M., Herrmann J., et al. Stabilisation of atherosclerotic plaques. Position paper of the european society of cardiology (esc) working group on atherosclerosis and vascular biology. Thromb. Haemost. 2011, 106:1-19.
13. Steinberg D. Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin. Mol. Nutr. Food Res. 2005, 49:995-998.
14. Hu X., Beeton C. Detection of functional matrix metalloproteinases by zymography. J. Vis. Exp. 2010.
15. Seimon T.A., Wang Y., Han S., Senokuchi T., Schrijvers D.M., Kuriakose G., et al. Macrophage deficiency of p38alpha mapk promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J. Clin. Invest. 2009, 119:886-898.
16. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (care) investigators. Circulation 1998, 98:839-844.
17. Libby P., Aikawa M. Mechanisms of plaque stabilization with statins. Am. J. Cardiol. 2003, 91:4B-8B.
18. Randolph G.J. Mechanisms that regulate macrophage burden in atherosclerosis. Circ. Res. 2014, 114:1757-1771.
19. Drechsler M., Megens R.T., van Zandvoort M., Weber C., Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010, 122:1837-1845.
20. Whitman S.C., Ramsamy T.A. Participatory role of natural killer and natural killer t cells in atherosclerosis: lessons learned from in vivo mouse studies. Can. J. Physiol. Pharmacol. 2006, 84:67-75.
21. Nakai Y., Iwabuchi K., Fujii S., Ishimori N., Dashtsoodol N., Watano K., et al. Natural killer t cells accelerate atherogenesis in mice. Blood 2004, 104:2051-2059.
22. Selathurai A., Deswaerte V., Kanellakis P., Tipping P., Toh B.H., Bobik A., et al. Natural killer (nk) cells augment atherosclerosis by cytotoxic-dependent mechanisms. Cardiovasc. Res. 2014, 102:128-137.
23. Hedrick C.C. Lymphocytes in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2015, 35:253-257.
24. Forero-Pena D.A., Gutierrez F.R. Statins as modulators of regulatory t-cell biology. Mediat. Inflamm. 2013, 2013:167086.
25. Rodriguez-Perea A.L., Montoya C.J., Olek S., Chougnet C.A., Velilla P.A. Statins increase the frequency of circulating cd4+ foxp3+ regulatory t cells in healthy individuals. J. Immunol. Res. 2015, 2015:762506.
26. Kofler S., Nickel T., Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin. Sci. (Lond.) 2005, 108:205-213.
27. Moreira D.M., da Silva R.L., Vieira J.L., Fattah T., Lueneberg M.E., Gottschall C.A. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease. Am. J. Cardiovasc. Drugs 2015, 15:1-11.
28. Nie P., Li D., Hu L., Jin S., Yu Y., Cai Z., et al. Atorvastatin improves plaque stability in apoe-knockout mice by regulating chemokines and chemokine receptors. PLoS One 2014, 9.
29. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 2008, 75:346-359.
30. Johnson J.L., George S.J., Newby A.C., Jackson C.L. Divergent effects of matrix metalloproteinase-3, metalloproteinase-7, metalloproteinase-9, and metalloproteinase-12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15575-15580.
31. Newby A.C., George S.J., Ismail Y., Johnson J.L., Sala-Newby G.B., Thomas A.C. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb. Haemost. 2009, 101:1006-1011.
32. Johnson J.L., Devel L., Czarny B., George S.J., Jackson C.L., Rogakos V., et al. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein e-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31:528-535.
33. Khurana R., Simons M., Martin J.F., Zachary I.C. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005, 112:1813-1824.
34. Bot I., Jukema J.W., Lankhuizen I.M., van Berkel T.J.C., Biessen E.A.L. Atorvastatin inhibits plaque development and adventitial neovascularization in apoe deficient mice independent of plasma cholesterol levels. Atherosclerosis 2011, 214:295-300.
35. Massaro M., Zampolli A., Scoditti E., Carluccio M.A., Storelli C., Distante A., et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc. Res. 2010, 86:311-320.
36. Kalkman E.A., van Suylen R.J., van Dijk J.P., Saxena P.R., Schoemaker R.G. Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat. J. Mol. Cell. Cardiol. 1995, 27:2483-2494.
37. Dai Z.H., Fukumoto Y., Shimokawa H. Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. J. Cardiol. 2012, 60:416-421.
38. Johnson J., Carson K., Williams H., Karanam S., Newby A., Angelini G., et al. Plaque rupture after short periods of fat feeding in the apolipoprotein e-knockout mouse-model characterization and effects of pravastatin treatment. Circulation 2005, 111:1422-1430.
39. Bea F., Blessing E., Bennett B., Levitz M., Wallace E.P., Rosenfeld M.E. Simvastatin promotes atherosclerotic plaque stability in apoe-deficient mice independently of lipid lowering. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1832-1837.
40. Monetti M., Canavesi M., Camera M., Parente R., Paoletti R., Tremoli E., et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoe-deficient mice. Pharmacol. Res. 2007, 55:441-449.
41. Nakamura K., Sasaki T., Cheng X.W., Iguchi A., Sato K., Kuzuya M. Statin prevents plaque disruption in apoe-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis 2009, 206:355-361.
42. Arnaboldi L., Corsini A. Do structural differences in statins correlate with clinical efficacy?. Curr. Opin. Lipidol. 2010, 21:298-304.